Serum Sclerostin Levels Positively Correlate with Lumbar Spinal Bone Mineral Density in Postmenopausal Women--the Six-month Effect of Risedronate and Teriparatide

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2011 Feb 10

PMID 21305266

Citations 52

Authors

S A Polyzos

A D Anastasilakis

C Bratengeier

W Woloszczuk

A Papatheodorou

E Terpos

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either lumbar spinal bone mineral density or T-score. Furthermore, serum sclerostin was increased after 6 months treatment with risedronate, whereas remained unchanged after 6 months teriparatide treatment.

Introduction: The primary aim of this study was the evaluation of serum sclerostin levels in postmenopausal women and their association with bone mineral density (BMD) and bone turnover markers. The secondary aim was the evaluation of treatment with either teriparatide (TPTD) or risedronate (RIS) on serum sclerostin levels in women with postmenopausal osteoporosis.

Methods: Women with postmenopausal osteoporosis, assigned to receive either TPTD (TPTD group, n = 13) or RIS (RIS group, n = 36) for 6 months, and non-osteoporotic early postmenopausal women (NOEP group, n = 13) were recruited. Main outcome measure was serum sclerostin levels.

Results: Serum sclerostin was higher in the NOEP group at baseline compared with either TPTD group (p = 0.007) or RIS group (p = 0.049). Sclerostin was positively correlated with both lumbar spinal (LS) BMD (r = 0.353; p = 0.005) and T-score (r = 0.501; p < 0.001) and negatively correlated with intact parathyroid hormone (r = -0.343; p = 0.024) at baseline. Multiple regression analysis showed that either LS BMD (Beta = 0.653; p = 0.018) or T-score (Beta = 0.711; p = 0.005) were independent predictors of serum sclerostin levels. No significant correlation was observed between serum sclerostin and bone turnover markers or estradiol at baseline. Sclerostin was significantly increased 6 months post-treatment in RIS group (p = 0.002), whereas remained statistically unaffected in the TPTD group.

Conclusions: Serum sclerostin is decreased in women with postmenopausal osteoporosis compared with non-osteoporotic early postmenopausal women and is positively correlated to either LS BMD or LS T-score. Furthermore, serum sclerostin was increased after 6 months treatment with RIS, whereas remained essentially unchanged after 6 months TPTD treatment.

Citing Articles

Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality.

Martiniakova M, Mondockova V, Kovacova V, Babikova M, Zemanova N, Biro R Diabetol Metab Syndr. 2024; 16(1):217.

PMID: 39238022 PMC: 11378428. DOI: 10.1186/s13098-024-01440-7.

Determinants of bone mass in older adults with normal- and overweight derived from the crosstalk with muscle and adipose tissue.

Walowski C, Herpich C, Enderle J, Braun W, Both M, Hasler M Sci Rep. 2023; 13(1):5030.

PMID: 36977715 PMC: 10050471. DOI: 10.1038/s41598-023-31642-4.

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease.

Ivanova M, Dao J, Kasaci N, Friedman A, Noll L, Goker-Alpan O Front Endocrinol (Lausanne). 2022; 13:1029130.

PMID: 36506070 PMC: 9730525. DOI: 10.3389/fendo.2022.1029130.

Osteoclast and Sclerostin Expression in Osteocytes in the Femoral Head with Risedronate Therapy in Patients with Hip Fractures: A Retrospective Comparative Study.

Lee H, Choi E, Jun H, Kim Y Medicina (Kaunas). 2022; 58(11).

PMID: 36363523 PMC: 9695260. DOI: 10.3390/medicina58111566.

Mechanical unloading aggravates bone destruction and tumor expansion in myeloma.

Tanimoto K, Hiasa M, Tenshin H, Teramachi J, Oda A, Harada T Haematologica. 2021; 107(3):744-749.

PMID: 34788982 PMC: 8883542. DOI: 10.3324/haematol.2021.278295.

References

Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico R . Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95(5):2248-53. DOI: 10.1210/jc.2010-0067. View

Mirza F, Padhi I, Raisz L, Lorenzo J . Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010; 95(4):1991-7. PMC: 2853994. DOI: 10.1210/jc.2009-2283. View

Moester M, Papapoulos S, Lowik C, Van Bezooijen R . Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010; 87(2):99-107. PMC: 2903685. DOI: 10.1007/s00223-010-9372-1. View

Trivedi R, Mithal A, Chattopadhyay N . Anabolics in osteoporosis: the emerging therapeutic tool. Curr Mol Med. 2010; 10(1):14-28. DOI: 10.2174/156652410791065372. View

Poole K, van Bezooijen R, Loveridge N, Hamersma H, Papapoulos S, Lowik C . Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19(13):1842-4. DOI: 10.1096/fj.05-4221fje. View

Drake M, Srinivasan B, Modder U, Peterson J, McCready L, Riggs B . Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010; 95(11):5056-62. PMC: 2968729. DOI: 10.1210/jc.2010-0720. View

Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler B . Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002; 417(6889):664-7. DOI: 10.1038/nature756. View

Anastasilakis A, Polyzos S, Avramidis A, Toulis K, Papatheodorou A, Terpos E . The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol (Oxf). 2009; 72(6):752-7. DOI: 10.1111/j.1365-2265.2009.03728.x. View

Tian X, Setterberg R, Li X, Paszty C, Ke H, Jee W . Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010; 47(3):529-33. DOI: 10.1016/j.bone.2010.05.032. View

10.

Lewiecki E . Emerging drugs for postmenopausal osteoporosis. Expert Opin Emerg Drugs. 2009; 14(1):129-44. DOI: 10.1517/14728210902766813. View

11.

Padhi D, Jang G, Stouch B, Fang L, Posvar E . Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2010; 26(1):19-26. DOI: 10.1002/jbmr.173. View

12.

Melton 3rd L, Looker A, Shepherd J, OConnor M, Achenbach S, Riggs B . Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int. 2005; 16(12):1558-64. DOI: 10.1007/s00198-005-1871-y. View

13.

Anastasilakis A, Goulis D, Polyzos S, Gerou S, Koukoulis G, Kita M . Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res. 2008; 40(4):281-5. DOI: 10.1055/s-2008-1046787. View

14.

Modder U, Hoey K, Amin S, McCready L, Achenbach S, Riggs B . Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2010; 26(2):373-9. PMC: 3179347. DOI: 10.1002/jbmr.217. View

15.

Anastasilakis A, Goulis D, Polyzos S, Gerou S, Koukoulis G, Efstathiadou Z . Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract. 2008; 62(6):919-24. DOI: 10.1111/j.1742-1241.2008.01768.x. View

16.

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M . Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10(5):537-43. DOI: 10.1093/hmg/10.5.537. View

17.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J . Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883-7. DOI: 10.1074/jbc.M413274200. View